REAL-WORLD COSTS AND HEALTHCARE RESOURCE UTILIZATION (HRU) PATTERNS IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (R/R-MCL) PATIENTS POST-IBRUTINIB FAILURE

被引：0
|
作者：
Lam, J. [1 ]
Lin, V. W. [2 ]
Purdum, A. G. [2 ]
机构：
[1] Univ Southern Calif, Los Angeles, CA USA
[2] Kite, Santa Monica, CA USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.227
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN103
引用
收藏
页码：S75 / S75
页数：1
相关论文
共 50 条
  • [21] Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) mantle cell lymphoma (MCL): A CIBMTR subgroup analysis by prior treatment.
    Kambhampati, Swetha
    Ahmed, Nausheen
    Hamadani, Mehdi
    Grover, Natalie Sophia
    Shadman, Mazyar
    Locke, Frederick L.
    Gerson, James M.
    Frank, Matthew Joshua
    Budde, Lihua Elizabeth
    Wang, Michael
    Hu, Zhen-Huan
    Nunes, Ana
    Dalton, David
    Kloos, Ioana
    Lee, Daniel
    Xu, Hairong
    Pasquini, Marcelo C.
    Herrera, Alex Francisco
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Healthcare Resource Utilization and Costs of Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Treated with Ibrutinib
    Yang, Xiaoqin
    Zanardo, Enrico
    Lejeune, Dominique
    De Nigris, Enrico
    Sarpong, Eric
    Farooqui, Mohammed Z. H.
    Laliberte, Francois
    BLOOD, 2022, 140 : 10911 - 10912
  • [23] Real-World Outcomes of Brexucabtagene Autoleucel ( Brexu-cel) for Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): A CIBMTR Subgroup Analysis of High-Risk Characteristics
    Kambhampati, Swetha
    Ahmed, Nausheen
    Hamadani, Mehdi
    Kim, Soyoung
    Hemmer, Michael T.
    Grover, Natalie S.
    Shadman, Mazyar
    Beitinjaneh, Amer
    Budde, L. Elizabeth
    Gerson, James
    Jacobson, Caron A.
    Locke, Frederick L.
    Nasta, Dwivedy S.
    Wang, Michael L.
    Weng, Wen-Kai
    Yan, Jiali
    Nunes, Ana
    Dalton, David
    Wu, James J.
    Abdeldaim, Amina
    Hu, Zhen-Huan
    Pasquini, Marcelo
    Herrera, Alex F.
    BLOOD, 2023, 142
  • [24] COST-EFFECTIVENESS ANALYSIS FOR ACALABRUTINIB IN THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (R/R MCL) IN CHINA
    Chang, S.
    He, X.
    VALUE IN HEALTH, 2024, 27 (06) : S95 - S95
  • [25] Understanding real world treatment patterns, healthcare resource utilization (HRU) and costs among metastatic renal cell carcinoma (mRCC) patients
    Copher, R.
    Byfield, S. Dacosta
    Buzinec, P.
    Korrer, S.
    Baig, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [26] Real-World Evidence of Relapsed/Refractory Mantle Cell Lymphoma Patients and Treatments: A Systematic Review
    Sancho, Juan-Manuel
    Sorigue, Marc
    Rubio-Azpeitia, Eva
    JOURNAL OF BLOOD MEDICINE, 2024, 15 : 239 - 254
  • [27] Management of Canadian Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the Real-World
    Peters, Anthea
    Nowakowski, Grzegorz S.
    Dabas, Rosy
    Amoloja, Theresa
    Xue, Zhenyi
    Koch, Caroline
    Waltl, Eva E.
    Fleury, Isabelle
    BLOOD, 2022, 140 : 3811 - 3813
  • [28] Real-World Effectiveness and Safety Outcomes of Acalabrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma
    Patel, Krish
    Teschemaker, Anna
    Tian, Hongping
    Pyrih, Nick
    Kolvenbag, Geert
    Patel, Shweta
    Wahlstrom, Svea K.
    Cui, Lianzhou
    BLOOD, 2024, 144 : 7745 - 7745
  • [29] Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population
    Cheng, Wendy Y.
    Sarda, Sujata P.
    Mody-Patel, Nikita
    Krishnan, Sangeeta
    Yenikomshian, Mihran
    Mahendran, Malena
    Lejeune, Dominique
    Yu, Louise H.
    Duh, Mei Sheng
    ADVANCES IN THERAPY, 2021, 38 (08) : 4461 - 4479
  • [30] Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population
    Wendy Y. Cheng
    Sujata P. Sarda
    Nikita Mody-Patel
    Sangeeta Krishnan
    Mihran Yenikomshian
    Malena Mahendran
    Dominique Lejeune
    Louise H. Yu
    Mei Sheng Duh
    Advances in Therapy, 2021, 38 : 4461 - 4479
12345